Summary
Stefan and Cusi's 2022 Lancet review examines the epidemiological and mechanistic interplay between non-alcoholic fatty liver disease and diabetes globally. The paper synthesises evidence on how these conditions share common metabolic drivers, particularly insulin resistance, and explores how their co-occurrence amplifies cardiovascular and liver-related morbidity. As a narrative review in a high-impact journal, it likely consolidates current understanding to inform clinical practice and public health strategy.
UK applicability
Given rising prevalence of both NAFLD and type 2 diabetes in the UK population, this global perspective on their shared pathophysiology is relevant to NHS prevention and management strategies. The review's findings may inform dietary and lifestyle interventions targeting metabolic syndrome in UK primary and secondary care.
Key measures
Prevalence of NAFLD and diabetes co-occurrence; metabolic risk factors; insulin resistance; fibrosis progression; cardiovascular outcomes
Outcomes reported
The study examined the bidirectional relationship between non-alcoholic fatty liver disease (NAFLD) and diabetes mellitus across diverse populations and healthcare settings. The paper synthesised evidence on shared metabolic pathways, prevalence patterns, and clinical outcomes linking these two conditions.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.